Ernexa Therapeutics Inc.
ERNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000748592
No open-market purchases or sales by Ernexa Therapeutics Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $236.2K in total; no superinvestor holds it.
Other share classesERNAW
13F holders, Q2 2024
Institutional positions in Ernexa Therapeutics Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −3 vs. Q1 2024
- Shares held
- 390.1K
- −19.1K (−4.7%) vs. Q1 2024
- Total value
- $712.4K
- −$268.7K (−27.4%) vs. Q1 2024
- New holders
- 2
- 3 more added
- Sold out
- 5
- 1 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $236.2K |
| Q1 2026 | 20 | $711.4K |
| Q4 2025 | 14 | $627.1K |
| Q3 2025 | 14 | $566.0K |
| Q2 2025 | 12 | $91.7K |
| Q1 2025 | 27 | $264.2K |
| Q4 2024 | 24 | $292.4K |
| Q3 2024 | 20 | $746.9K |
| Q2 2024 | 20 | $712.4K |
| Q1 2024 | 23 | $981.1K |
| Q4 2023 | 20 | $636.9K |
| Q3 2023 | 22 | $728.4K |
| Q2 2023 | 20 | $750.2K |
| Q1 2023 | 21 | $1.14M |
| Q4 2022 | 20 | $1.19M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Ernexa Therapeutics Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 22 | $0 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 4 | $8 | 0.00% | 00.0% | Unchanged |
| Aspire Private Capital, LLC | 10 | $18 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 14 | $25 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 15 | $27 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 19 | $34 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 29 | $53 | 0.00% | +29 | New |
| Morgan Stanley | 50 | $92 | 0.00% | 00.0% | Unchanged |
| Activest Wealth Management | 50 | $92 | 0.00% | +50 | New |
| Montag A & Associates Inc | 212 | $388 | 0.00% | +71+50.4% | Added |
| Tower Research Capital LLC (TRC) | 5,174 | $9.47K | 0.00% | +1,091+26.7% | Added |
| Baldwin Brothers Inc | 8,544 | $15.6K | 0.00% | 00.0% | Unchanged |
| Avidian Wealth Solutions, LLC | 14,798 | $27.1K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 14,973 | $27.4K | 0.00% | −646−4.1% | Reduced |
| Geode Capital Management, LLC | 23,719 | $43.0K | 0.00% | +1,231+5.5% | Added |
| Vanguard Group Inc | 26,099 | $47.8K | 0.00% | 00.0% | Unchanged |
| CI Private Wealth, LLC | 50,398 | $91.2K | 0.00% | 00.0% | Unchanged |
| Sippican Capital Advisors | 72,800 | $133.2K | 0.11% | 00.0% | Unchanged |
| Naviter Wealth, LLC | 78,796 | $144.2K | 0.02% | 00.0% | Unchanged |
| Cypress Point Wealth Management, LLC | 94,375 | $172.7K | 0.08% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −10,091−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −10,083−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −741−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −10−100.0% | Sold out |